10-Q: Clover Health Reports Strong Q1 2026 Results

Clover Health Investments, Corp. announced a significant turnaround in its Q1 2026 financial performance, reporting a net income of $27.3 million compared to a net loss in the prior year.

Summary

• Clover Health reported a net income of $27.3 million for the first quarter ended March 31, 2026, a substantial improvement from a net loss of $1.3 million in the same period of 2025.
• Total revenues surged by 62.0% to $749.2 million, driven by a 62.9% increase in premiums earned, net, to $744.2 million.
• Net medical claims incurred also rose significantly, up 66.8% to $589.6 million, reflecting membership growth.
• The company's Insurance Benefits Expense Ratio (BER) was 86.5%, a slight increase from 86.1% in the prior year.
• Adjusted EBITDA showed a strong increase of 56.6% to $40.3 million, indicating improved operational profitability.
• Cash and cash equivalents increased to $173.3 million from $78.3 million at the end of 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, a return to profitability, and improved operational metrics, indicating a healthy recovery and positive trajectory.

Positives

• Achieved net income of $27.3 million, a significant turnaround from a net loss in the prior year.
• Total revenues increased by 62.0% to $749.2 million, driven by strong premium growth.
• Premiums earned, net, grew by 62.9% to $744.2 million, indicating successful member acquisition and retention.
• Average Medicare Advantage membership increased by approximately 51% year-over-year.
• Adjusted EBITDA increased by 56.6% to $40.3 million, demonstrating enhanced operational efficiency.
• Cash and cash equivalents saw a substantial increase, reaching $173.3 million.
• The company's PPO plans are now being paid on 4.0 stars compared to 3.5 stars in the prior period, potentially improving revenue.

Negatives

• Net medical claims incurred increased by 66.8%, outpacing premium revenue growth slightly.
• General and administrative expenses increased by 47.3%, primarily due to higher professional and broker fees.
• The ratio of current year medical claims paid as a percentage of current year net medical claims incurred was 62.0% for Q1 2026, down from 64.0% in Q1 2025, indicating a slower claims processing rate.
• An unfavorable development of $6.4 million was recognized in unpaid claims during the quarter, stemming from actual claims experience differing from estimates.

Risks

• The company faces risks related to changes in government healthcare policy, including potential impacts from CMS's increased volume of Risk Adjustment Data Validation (RADV) audits.
• Fluctuations in interest rates and general economic conditions could impact investment income and overall financial performance.
• Competition in the Medicare Advantage market remains intense, potentially affecting market share and profitability.
• The company's reliance on technology, particularly Clover Assistant, carries risks associated with development, adoption, and market acceptance.
• The company's ability to effectively manage its member base and provider network is critical and subject to various operational and regulatory challenges.
• Potential for future litigation and regulatory proceedings remains a risk, although the SEC investigation concluded without an enforcement action.

Future Outlook

The company projects that its current cash, cash equivalents, investments, and projected cash flows will be sufficient to meet operating and regulatory requirements for the next 12 months. Future capital requirements will depend on business growth, opportunities, and unforeseen circumstances, potentially necessitating additional equity or debt financing.

Management Comments

• Clover Health's vision is to empower every physician with the technology to identify, manage, and treat chronic diseases earlier.
• The company aims to provide high-quality, affordable healthcare for all Medicare beneficiaries, offering competitive out-of-pocket costs.
• The use of Clover Assistant and related data insights is believed to improve clinical decision-making through a highly scalable platform.
• The company is focused on member growth and retention, which drives revenue, expands brand awareness, and generates data to improve Clover Assistant.

Industry Context

StockSavvy.ai notes that Clover Health's Q1 2026 results reflect a positive trend in the Medicare Advantage market, characterized by increasing enrollment and a focus on technology-driven care management. The company's strategy to leverage its Clover Assistant platform for both internal operations and external licensing via Counterpart Health positions it to capitalize on the growing demand for value-based care solutions.

Comparison to Industry Standards

• Clover Health's Insurance Benefits Expense Ratio (BER) of 86.5% is within the typical range for Medicare Advantage plans, though specific industry benchmarks can vary significantly by plan type and region.
• The company's revenue growth of 62.0% significantly outpaces the general healthcare industry growth rate, indicating strong performance in its specific market segment.
• The increase in star ratings for its PPO plans (from 3.5 to 4.0) is a positive indicator, as higher star ratings are directly linked to increased reimbursements from CMS, a key driver for Medicare Advantage insurers.
• While specific competitor data is not provided in the filing, the reported Adjusted EBITDA growth suggests improved operational efficiency compared to the prior year, a trend likely mirrored by successful competitors in the managed care space.

Legal Proceedings

• The SEC investigation related to disclosures and business aspects, as well as matters discussed in a Hindenburg Research article, concluded without the SEC Staff recommending an enforcement action against the Company.

Related Party Transactions

• The Company receives administrative services from Medical Records Exchange, LLC (Credo), in which Vivek Garipalli, Executive Chairman, is an indirect owner. Expenses were $1.8 million for Q1 2026.
• The Company has a contract with Thyme Care, Inc. for oncology care management services. Vivek Garipalli is a board member and holds a less than 5% equity interest in Thyme Care. Expenses were $4.0 million for Q1 2026.
• The Company has a Master Services Agreement with Guidehealth, LLC for value-based care enablement. Thomas Tran, a Board member, serves as a director and holds a less than 5% ownership interest in Guidehealth. No expense recognized in Q1 2026.
• The Company holds a non-controlling equity investment in Character Biosciences (CB), where Vivek Garipalli serves on the Board of Directors. No transactions occurred between the Company and CB during the periods presented.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance and return to profitability, potentially leading to increased stock value.
• Members: Continued access to Medicare Advantage plans with a focus on quality care and potentially lower out-of-pocket costs.
• Physicians: Continued access to technology tools like Clover Assistant to aid in patient care and chronic disease management.
• Employees: Potential for continued investment in growth and technology, supporting job security and development opportunities.
• Regulators: Ongoing compliance with healthcare regulations, with the recent conclusion of the SEC investigation being a positive development.

Next Steps

• Continue to focus on empowering physicians with technology to identify and manage chronic diseases.
• Expand the reach of Clover Assistant technology externally through Counterpart Assistant.
• Manage membership growth and retention to drive revenue and gather data for insights.
• Monitor and adapt to changes in government healthcare policy and regulations.
• Continue to manage medical claims and operational expenses to maintain profitability.

Key Dates

Recommendation

The company has demonstrated a significant turnaround, achieving profitability and substantial revenue growth in Q1 2026. The strategic focus on technology, coupled with improved operational metrics and a positive outlook for the Medicare Advantage market, suggests strong future potential. The resolution of the SEC investigation removes a key overhang. While risks remain, the current performance and strategic positioning warrant a strong buy recommendation.

Keywords

Clover Health, CLOV, 10-Q, Quarterly Report, Medicare Advantage, Health Insurance, Financial Results, Premiums Earned, Medical Claims, Adjusted EBITDA, Clover Assistant, Healthcare Technology